Key Insights From the DEBBRAH and HER2CLIMB-02 Studies

Opinion
Video

Panelists discuss a brief overview of recent data on combination systemic therapies for the treatment of advanced HER2+ breast cancer, including studies such as DESTINY-Breast03, DEBBRAH, HER2CLIMB-02, and EMILIA, and they analyze which patient populations may benefit most from each therapy option based on the available data.

  1. Dr Iyengar: Please provide a brief overview of other recent data in combination systemic therapies for the treatment of advanced RCC. 
    1. DESTINY-Breast03
    2. DEBBRAH
    3. HER2CLIMB-02
    4. EMILIA
  2. Given the available data, for which patient population do you prefer each therapy option and why?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective

Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective

ONCOLOGY Staff
December 29th 2024
Article

In a From All Angles program, a patient and her treating physician spoke about the initial diagnosis, care coordination, communication, and the adverse effects observed.